[{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Eucure Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Toripalimab","moa":"||CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase II","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ ISU ABXIS","highestDevelopmentStatusID":"8","companyTruncated":"ISU ABXIS \/ ISU ABXIS"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Petrovax","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Licensing Agreement","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Petrovax","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Petrovax"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Petrovax","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ ISU ABXIS","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ ISU ABXIS"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Abcertin","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Eucure Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISU ABXIS \/ ISU ABXIS","highestDevelopmentStatusID":"2","companyTruncated":"ISU ABXIS \/ ISU ABXIS"}]

Find Clinical Drug Pipeline Developments & Deals by ISU ABXIS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Fabagal (Agalsidase Beta) is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fabry Disease.

                          Product Name : Fabagal

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          October 12, 2023

                          Lead Product(s) : Agalsidase Beta

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.

                          Product Name : Fabagal

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          October 02, 2023

                          Lead Product(s) : Agalsidase Beta

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : Petrovax

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single agent or in combination with anti-PD-1 monoclonal antibody drugs, YH003 demonstrated strong anti-tumor effects against multiple tumor.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 01, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Eucure Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen’s humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for...

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          October 31, 2022

                          Lead Product(s) : YH003,Toripalimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Eucure Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.

                          Product Name : Abcertin

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          October 22, 2022

                          Lead Product(s) : Imiglucerase

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.

                          Product Name : Abcertin

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          August 12, 2022

                          Lead Product(s) : Imiglucerase

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).

                          Product Name : Fabagal

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          January 26, 2022

                          Lead Product(s) : Agalsidase Beta

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Petrovax

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Abcertin is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gaucher Disease.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 09, 2021

                          Lead Product(s) : Abcertin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : ISU104 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          June 11, 2018

                          Lead Product(s) : ISU104

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : ISU304 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemophilia B.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 14, 2017

                          Lead Product(s) : ISU304

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Catalyst Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank